![](/static/img/rhino/hero-right-sm-mb.png)
Continuous, once-daily oral dosing 1
Straightforward dosing for patients with no pre-planned treatment breaksa
LYTGOBI is taken
![LYTGOBI has as starting dose of 20 mg, or five 4-mg tablets](https://taihocorporate-lytgobi-media-stage.s3.us-west-2.amazonaws.com/original_images/lytgobi-20-mg-dose.png)
At a starting dose of 20 mg
taken as five 4-mg tablets. LYTGOBI tablets should be swallowed whole. Do not crush, chew, split, or dissolve tablets
![LYTGOBI is taken orally with or without food](https://taihocorporate-lytgobi-media-stage.s3.us-west-2.amazonaws.com/original_images/lytgobi-oral-dosing.png)
Orally with or without food
Advise patients to avoid grapefruit products during treatment with LYTGOBI
![LYTGOBI is taken at the same time each day](https://taihocorporate-lytgobi-media-stage.s3.us-west-2.amazonaws.com/original_images/dosing-timing-icon.png)
At the same time each day
until disease progression or unacceptable toxicity. If a dose is missed for more than 12 hours or if vomiting occurs, resume dosing with the next scheduled dose
- aTreatment breaks may be required if toxicity occurs with LYTGOBI.
Remember: Day 1 is row 1. Each row of tablets equals one daily dose. Each card contains one week's worth of LYTGOBI tablets
![LYTGOBI® (futibatinib) tablets exterior packaging](https://taihocorporate-lytgobi-media-stage.s3.us-west-2.amazonaws.com/original_images/lytgobi-tablets-exterior-packaging.png)
![LYTGOBI® (futibatinib) tablets interior packaging](https://taihocorporate-lytgobi-media-stage.s3.us-west-2.amazonaws.com/original_images/lytgobi-tablets-interior-packaging.png)
![LYTGOBI® (futibatinib) 4 mg tablet](https://taihocorporate-lytgobi-media-stage.s3.us-west-2.amazonaws.com/original_images/lytgobi-4-mg-tablet.png)
Tablet shown is not actual size.
![LYTGOBI® (futibatinib) tablets blister pack](https://taihocorporate-lytgobi-media-stage.s3.us-west-2.amazonaws.com/original_images/lytgobi-tablets-blister-pack.png)
Alternative DosePaks are available to support dose modifications if needed
Recommended dose reductions for adverse reaction management:
- First dose reductionb: 16 mg (four 4-mg tablets) orally once daily (28 count pack)
- Second dose reductionb: 12 mg (three 4-mg tablets) orally once daily (21 count pack)
bPermanently discontinue LYTGOBI if unable to tolerate 12 mg once daily.
![LYTGOBI® (futibatinib) tablets 28 tablet DosePak](https://taihocorporate-lytgobi-media-stage.s3.us-west-2.amazonaws.com/original_images/lytgobi_28_tablet_dosepak.png)
28 count
![LYTGOBI® (futibatinib) tablets 21 tablet DosePak](https://taihocorporate-lytgobi-media-stage.s3.us-west-2.amazonaws.com/original_images/lytgobi_21_tablet_dosepak.png)
21 count
References:
LYTGOBI [package insert]. Princeton, NJ: Taiho Oncology, Inc.; 2022.